Acera Surgical Announces Positive Results from Clinical Study Examining The Use of Restrata® Wound Matrix In Healing Chronic Lower Extremity Wounds
St. Louis, MO—April 18, 2018— Acera Surgical Inc., the industry leader in implantable nanomedical scaffolds, has been selected to present […]
Acera Surgical Publishes Manuscript Highlighting the Mechanism of Action of Nanofabricated Restrata™ Wound Matrix
St. Louis, MO— October 5th, 2017— Acera Surgical Inc., a bioscience company dedicated to the commercialization of fully synthetic electrospun scaffolds for medical applications, announced today the publication of scientific manuscript describing the mechanism of action of the Restrata™ Wound […]Read More
St. Louis, MO. September 15, 2017- Acera is starting a clinical trial on Restrata™ Wound Matrix with a focus on diabetic foot ulcer. Acera will be working with Telos Partner to manage the clinical trial. The study is titled: “Clinical Outcomes […]Read More
St. Louis, MO—September 5, 2017— Acera Surgical Inc., a company dedicated to the development and commercialization of fully synthetic electrospun scaffolds for medical applications, announced today the publication of results from the pre-clinical study of the efficacy of Restrata Wound […]Read More
Acera Surgical to Present Results of Study on the Use of Restrata™ Wound Matrix in Healing Full-thickness Wounds at Fall Symposium on Advanced Wound Care
St. Louis, MO—August 29, 2017— Acera Surgical Inc. has been selected to present the results from a study involving the Restrata™ Wound Matrix at the Fall 2017 Symposium on Advanced Wound Care (“SAWC”), being held in Las Vegas, Nevada, from October […]Read More
Acera Surgical Inc., (“Acera”) a bioscience company located in St. Louis, MO received 510(k) clearance from the Food and Drug Administration (FDA) for its innovative wound care product, the Restrata™ Wound Matrix on April 26th. Restrata™ is a fully-synthetic electrospun wound […]Read More
ST.LOUIS – Acera Surgical, Inc., a Washington University startup co-founded by former WU student Dr. Matthew MacEwan, received 510(k) clearance from the Food and Drug Administration (FDA) for its first clinical product, the Cerafix® Dura Substitute. With the approval from […]Read More
ACERA Selected as One of the “Best University Startups 2016” by National Council of Entrepreneurial Tech Transfer
Acera Surgical has been selected as one of the “Best University Startups 2016” by National Council of Entrepreneurial Tech Transfer (NCET2).
NCET2 recognizes that Startup Officers are the backbone of any university’s research commercialization program. They work to support the world’s most […]
Acera Surgical has been selected to present at the 2016 Texas Life Science Venture Forum in Houston, Texas on May 26th, 2016.
Texas Life Science Forum is the premiere life science venture conference in the Southwest. The Forum is the most comprehensive showcase and […]